Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Maxygen has initiated a Phase I clinical study to evaluate CTLA4-Ig therapeutic, which is being developed for the treatment of rheumatoid arthritis and other autoimmune indications.
Subscribe to our email newsletter
The randomised, double-blind, placebo-controlled, dose escalation study will be conducted at one centre in the US and is designed to enroll 65 subjects in eight dose cohorts.
The primary objective of the study is to evaluate the safety, tolerability, and pharmacokinetics of single ascending intravenous doses of CTLA4-Ig therapeutic in healthy male and female subjects.
The secondary objective of the study is to evaluate the pharmacodynamics of the CTLA4-Ig therapeutic.
CTLA4-Ig therapeutic is being developed by Perseid Therapeutics, Maxygen’s majority-owned subsidiary, in partnership with Astellas Pharma – which is sponsoring the clinical trial.